| Literature DB >> 36015346 |
Philippe-Henri Secretan1, Maxime Annereau1,2, Willy Kini-Matondo3, Bastien Prost4, Jade Prudhomme1, Lina Bournane1, Muriel Paul3,5, Najet Yagoubi1, Hassane Sadou-Yayé1,6, Bernard Do1,3.
Abstract
Nirmatrelvir is an antiviral drug approved for the treatment of COVID-19. The available dosage form consists of tablets marketed under the brand name PAXLOVID®. Although knowledge of nirmatrelvir's intrinsic stability may be useful for any potential development of other pharmaceutical forms, no data regarding this matter is available to date. Preliminary forced degradation studies have shown that the molecule is stable under oxidative and photolytic conditions, while hydrolytic conditions, both acidic and basic, have proven deleterious. Indeed, the molecule presents a priori several functions that can undergo hydrolysis, i.e., three amide moieties and a nitrile function. However, considering the degradation products formed under forced conditions and which were detected and identified by LC-UV-HRMSn, the hydrolysis process leading to their formation is selective since it involved only 2 of the 4 hydrolysable functions of the molecule. Ab initio studies based on density functional theory (DFT) have helped better understand these reactivity differences in aqueous media. Some hydrolyzable functions of nirmatrelvir differ from others in terms of electrostatic potential and Fukui functions, and this seems to correlate with the forced degradation outcomes.Entities:
Keywords: DFT; ab initio calculations; degradation products; mass spectrometry; preformulation studies; selective hydrolysis
Year: 2022 PMID: 36015346 PMCID: PMC9412384 DOI: 10.3390/pharmaceutics14081720
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1(a) LC-HR-MS full scan chromatograms of nirmatrelvir: standard solution (black), after 3 h at pH = 13 ± 0.2 (blue), after one week at pH = 1 ± 0.2 and at 40 °C (red). (b) Extracted ion chromatograms obtained from the full scan chromatogram recorder after 3 h at pH = 13 ± 0.2: black m/z [421.5–422.5] uma, red: m/z [403.5–404.5] uma, light blue: m/z [517.5–518.5] uma.
Figure 2Proposed fragmentation pattern of protonated nirmatrelvir. The structure of the base peak-ion is circled in green.
Figure 3Proposed fragmentation pattern of protonated DP517 ([DP517+H]+).
Figure 4Proposed fragmentation pattern of protonated DP403 ([DP403+H]+).
Figure 5Proposed fragmentation pattern of protonated DP421 ([DP421+H]+).
Figure 6Proposed nirmatrelvir’s degradation pathways under basic conditions.
Figure 7Proposed nirmatrelvir’s degradation pathways under acidic conditions leading to the formation of DP517 (a) and DP403 (b).
Figure 8(a,b) Structure of optimized geometry of nirmatrelvir’s main conformer at pH = 1; (c,d) mapped electrostatic potential; and (e,f) mapped Fukui f− function. Regions with the lowest and highest values are mapped in red and purple, respectively.
Figure 9(a,b) Structure of optimized geometry of nirmatrelvir’s main conformer at pH = 13; (c,d) associated mapped electrostatic potential; and (e,f) mapped Fukui f + function. Regions with lowest and highest values are mapped in red and purple, respectively.